Literature DB >> 17420256

M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721.

Roberta Faccio1, Sunao Takeshita, Graziana Colaianni, Jean Chappel, Alberta Zallone, Steven L Teitelbaum, F Patrick Ross.   

Abstract

M-CSF is known to induce cytoskeletal reorganization in macrophages and osteoclasts by activation of phosphatidylinositol 3-kinase (PI3K) and c-Src, but the detailed mechanisms remain unclear. We find, unexpectedly, that tyrosine (Tyr) to phenylalanine (Phe) mutation of Tyr-721, the PI3K binding site in the M-CSF receptor c-Fms, fails to suppress cytoskeletal remodeling or actin ring formation. In contrast, mutation of c-Fms Tyr-559 to Phe blocks M-CSF-induced cytoskeletal reorganization by inhibiting formation of a Src Family Kinase SFK.c-Cbl.PI3K complex and the downstream activation of Vav3 and Rac, two key mediators of actin remodeling. Using an add-back approach in which specific Tyr residues are reinserted into c-Fms inactivated by the absence of all seven functionally important Tyr residues, we find that Tyr-559 is necessary but not sufficient to transduce M-CSF-dependent cytoskeletal reorganization. Furthermore, this same add-back approach identifies important roles for Tyr-697 and Tyr-721 in collaborating with Tyr-559 to recruit a multimeric signaling complex that can transduce signals from c-Fms to the actin cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420256     DOI: 10.1074/jbc.M610937200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk.

Authors:  Wei Zou; Jennifer L Reeve; Yuli Liu; Steven L Teitelbaum; F Patrick Ross
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

3.  CSF-1-induced Src signaling can instruct monocytic lineage choice.

Authors:  Max Endele; Dirk Loeffler; Konstantinos D Kokkaliaris; Oliver Hilsenbeck; Stavroula Skylaki; Philipp S Hoppe; Axel Schambach; E Richard Stanley; Timm Schroeder
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 4.  The diverse functions of Src family kinases in macrophages.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  Front Biosci       Date:  2008-05-01

5.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts.

Authors:  Virginie Vives; Mélanie Laurin; Gaelle Cres; Pauline Larrousse; Zakia Morichaud; Danièle Noel; Jean-François Côté; Anne Blangy
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

Review 6.  Regulation of tyrosine phosphorylation in macrophage phagocytosis and chemotaxis.

Authors:  Haein Park; Dan Ishihara; Dianne Cox
Journal:  Arch Biochem Biophys       Date:  2011-02-26       Impact factor: 4.013

7.  Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion.

Authors:  Natalia G Sampaio; Wenfeng Yu; Dianne Cox; Jeffrey Wyckoff; John Condeelis; E Richard Stanley; Fiona J Pixley
Journal:  J Cell Sci       Date:  2011-05-24       Impact factor: 5.285

8.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo.

Authors:  Hyun-Ju Kim; Kaihua Zhang; Lihong Zhang; F Patrick Ross; Steven L Teitelbaum; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

Review 9.  Osteoclast motility: putting the brakes on bone resorption.

Authors:  Deborah V Novack; Roberta Faccio
Journal:  Ageing Res Rev       Date:  2009-09-27       Impact factor: 10.895

Review 10.  Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.

Authors:  Jeske J Smink; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2009-11-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.